Renaissance Technologies’s Nephros NEPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$277K Sell
77,504
-21,896
-22% -$71.2K ﹤0.01% 2799
2026
Q1
$296K Sell
99,400
-4,372
-4% -$17.5K ﹤0.01% 2792
2025
Q4
$506K Buy
103,772
+21,272
+26% +$109K ﹤0.01% 2571
2025
Q3
$390K Buy
82,500
+71,600
+657% +$281K ﹤0.01% 2894
2025
Q2
$44.6K Buy
+10,900
New +$29.1K ﹤0.01% 3410
2024
Q4
Sell
-24,444
Closed -$41.8K 3788
2024
Q3
$41.8K Sell
24,444
-16,556
-40% -$32.7K ﹤0.01% 3360
2024
Q2
$86.5K Sell
41,000
-200
-0.5% -$432 ﹤0.01% 3209
2024
Q1
$90K Buy
+41,200
New +$131K ﹤0.01% 3392
2023
Q3
Sell
-13,705
Closed -$21K 3953
2023
Q2
$21K Sell
13,705
-9,495
-41% -$14K ﹤0.01% 3766
2023
Q1
$25K Sell
23,200
-8,864
-28% -$10.2K ﹤0.01% 3790
2022
Q4
$37K Buy
32,064
+9,764
+44% +$10.4K ﹤0.01% 3853
2022
Q3
$20K Buy
+22,300
New +$31.5K ﹤0.01% 3897
2022
Q2
Sell
-20,317
Closed -$89K 4456
2022
Q1
$89K Buy
+20,317
New +$96.4K ﹤0.01% 3816
2020
Q3
Sell
-17,900
Closed -$150K 3576
2020
Q2
$150K Buy
+17,900
New +$142K ﹤0.01% 3213

Other funds holding NEPH

Renaissance Technologies's NEPH Position: Q2 2026 in Review

Renaissance Technologies reduced its Nephros (NEPH) stake by 22% in Q2 2026, selling an estimated $71.2K and leaving 77,504 shares worth $277K. The position accounts for ﹤0.01% of the portfolio, ranked #2799.

Renaissance Technologies first reported a position in NEPH in Q2 2020 and has held it in 14 quarters since. The position peaked at $506K in Q4 2025. 29 funds tracked by Wall St. Rank hold NEPH as of Q2 2026.

  • Renaissance Technologies held 77,504 shares of Nephros worth $277K as of Q2 2026.
  • Renaissance Technologies sold 21,896 Nephros shares in Q2 2026, an estimated $71.2K.
  • Nephros made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2799 holding.
  • Renaissance Technologies first reported a position in Nephros in Q2 2020 and has held it in 14 quarters since.
  • Renaissance Technologies's Nephros position peaked at $506K in Q4 2025.
  • 29 funds tracked by Wall St. Rank held Nephros as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.